clinical trial · NCT06826612
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
Hoffmann-La Roche·phase2·recruiting·n = 53
Huntington DiseaseSPK-10001Placebo Surgery Control
brief summary
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
started
Feb 21, 2025
primary completion
Jan 12, 2035
completion
Jan 12, 2035
last updated
Apr 17, 2026
official title
A Phase 1/2, Randomized, Sequential, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a One-Time, Bilateral, Intraparenchymal Infusion of SPK-10001 Into the Caudate and Putamen in Participants With Huntington's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol